{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:29:33Z","timestamp":1761560973163},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.gtc.2004.03.001","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T14:53:30Z","timestamp":1113836010000},"page":"407-420","source":"Crossref","is-referenced-by-count":21,"title":["Methotrexate in inflammatory bowel disease"],"prefix":"10.1016","volume":"33","author":[{"given":"Brian G","family":"Feagan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Alfadhli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2004.03.001_BIB1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.03.001_BIB2","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.03.001_BIB3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1572-0241.2002.05596.x","article-title":"Corticosteroids in Crohn's disease","volume":"97","author":"Yang","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM198503283121310","article-title":"Methotrexate in rheumatoid arthritis","volume":"312","author":"Klippel","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.03.001_BIB5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.1964.03070100037007","article-title":"Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients","volume":"189","author":"Black","year":"1964","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2004.03.001_BIB6","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/art.1780381213","article-title":"Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis: a forty-eight-week controlled clinical trial with radiologic outcome assessment","volume":"38","author":"Willkens","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2004.03.001_BIB7","doi-asserted-by":"crossref","first-page":"49S","DOI":"10.1111\/1523-1747.ep12505777","article-title":"Cytotoxic and immunologic effects of methotrexate in psoriasis","volume":"95","author":"Weinstein","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB8","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.03.001_BIB9","series-title":"The pharmacological basis of therapeutics","author":"Goodman","year":"1996"},{"key":"10.1016\/j.gtc.2004.03.001_BIB10","first-page":"1845","article-title":"A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing","volume":"20","author":"Jundt","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0889-857X(05)70359-8","article-title":"Pharmacology and pharmacokinetics of methotrexate in rheumatic disease: practical issues in treatment and design","volume":"23","author":"Hillson","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.gtc.2004.03.001_BIB12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","article-title":"Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis","volume":"30","author":"Bannwarth","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.gtc.2004.03.001_BIB13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.7326\/0003-4819-121-11-199412010-00002","article-title":"Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis","volume":"121","author":"Morgan","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2004.03.001_BIB14","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1172\/JCI116884","article-title":"The anti-inflammatory mechanism of methotrexate","volume":"92","author":"Cronstein","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gtc.2004.03.001_BIB15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ibd.3780050305","article-title":"Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate","volume":"5","author":"Egan","year":"1999","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2004.03.001_BIB16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1155\/1996\/213596","article-title":"Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up","volume":"10","author":"Malatjalian","year":"1996","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/hep.1840140525","article-title":"Hepatotoxicity in a rat model caused by orally administered methotrexate","volume":"14","author":"Hall","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2004.03.001_BIB18","first-page":"1337","article-title":"Methotrexate-induced chronic liver injury: guidelines for detection and prevention","volume":"88","author":"Lewis","year":"1988","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB19","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1111\/j.1572-0241.2000.03287.x","article-title":"Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease","volume":"95","author":"Te","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.03.001_BIB21","first-page":"1121","article-title":"Pancytopenia associated with low dose methotrexate therapy: a regional survey","volume":"20","author":"Al-Awadhi","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB22","first-page":"1164","article-title":"Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors: four case reports and a review of the literature","volume":"14","author":"Searles","year":"1987","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0002-9343(90)90522-F","article-title":"Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease","volume":"88","author":"Kozlowski","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.gtc.2004.03.001_BIB24","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn's disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.03.001_BIB25","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(78)92524-2","article-title":"Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease","volume":"2","author":"O'Donoghue","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2004.03.001_BIB26","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A Controlled double blind study of azathioprine in the management of Crohn's disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.03.001_BIB27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.7326\/0003-4819-123-2-199507150-00009","article-title":"Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis","volume":"122","author":"Pearson","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2004.03.001_BIB28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study","volume":"302","author":"Present","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.03.001_BIB29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-111-8-641","article-title":"6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity","volume":"111","author":"Present","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2004.03.001_BIB30","first-page":"546","article-title":"Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980\u20131995: results from the National Ambulatory Medical Care Surveys","volume":"26","author":"Ward","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB31","first-page":"2331","article-title":"How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey","volume":"25","author":"Maetzel","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB32","first-page":"2036","article-title":"Current treatment by United States and Canadian pediatric rheumatologists","volume":"26","author":"Cron","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB33","first-page":"64","article-title":"Combination treatment of rheumatoid arthritis using azathioprine and methotrexate: a 48 week controlled clinical trial","volume":"44","author":"Willkens","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/0003-4819-110-5-353","article-title":"Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease","volume":"110","author":"Kozarek","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2004.03.001_BIB35","first-page":"CD003459","article-title":"Methotrexate for induction of remission in refractory Crohn's disease","volume":"1","author":"Alfadhli","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gtc.2004.03.001_BIB36","first-page":"2203","article-title":"Methotrexate in chronic active Crohn's disease: a double blind, randomized, Israeli multicentre trial","volume":"92","author":"Oren","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB37","first-page":"1724","article-title":"Methotrexate in Crohn's disease: results of a randomized double-blind, placebo-controlled trial","volume":"46","author":"Arora","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.gtc.2004.03.001_BIB38","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1200\/JCO.1988.6.12.1882","article-title":"Pharmacokinetics of subcutaneous methotrexate","volume":"6","author":"Balis","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/art.1780330112","article-title":"Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis","volume":"33","author":"Brooks","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2004.03.001_BIB40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0009-9236(99)70119-0","article-title":"Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease","volume":"65","author":"Egan","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.gtc.2004.03.001_BIB41","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/39.10.1102","article-title":"Do patients with rheumatoid arthritis established on methotrexate and folic acid 5mg daily need to continue folic acid supplements long term?","volume":"39","author":"Griffith","year":"2000","journal-title":"Rheumatology"},{"key":"10.1016\/j.gtc.2004.03.001_BIB42","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/rheumatology\/39.7.812","article-title":"Daily folate supplements is adequate prophylaxis against methotrexate-induced nausea and vomiting and avoids the need for expensive anti-emetic prescription","volume":"39","author":"Lorenzi","year":"2000","journal-title":"Rheumatol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB43","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/art.1780371221","article-title":"Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. American College of Rheumatology","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2004.03.001_BIB44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2036.2001.00908.x","article-title":"Efficacy of parenteral methotrexate in refractory Crohn's disease","volume":"15","author":"Chong","year":"2001","journal-title":"Aliment Pharm"},{"key":"10.1016\/j.gtc.2004.03.001_BIB45","series-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease (Cochrane Review). The Cochrane Library (database on disk and CD-ROM) (3)","author":"Sandborn","year":"2002"},{"key":"10.1016\/j.gtc.2004.03.001_BIB46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1590-8658(03)00372-4","article-title":"Comparison between methotrexate and azathioprine in the treatment of chronic active chron's disease: a randomised, investigator blind study","volume":"35","author":"Ardizzone","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gtc.2004.03.001_BIB47","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusion of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2004.03.001_BIB48","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.03.001_BIB49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/bmj.305.6844.20","article-title":"Randomized controlled trial of azathioprine withdrawal in ulcerative colitis","volume":"305","author":"Hawthorne","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.gtc.2004.03.001_BIB50","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1053\/gast.1996.v110.pm8613046","article-title":"Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial","volume":"110","author":"Oren","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.03.001_BIB51","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00042737-200012110-00010","article-title":"6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease","volume":"12","author":"Mate-Jimenez","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2004.03.001_BIB52","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJM199508313330917","article-title":"Methotrexate for Crohn's disease","volume":"333","author":"Korelitz","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.03.001_BIB53","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for Crohn's disease","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.03.001_BIB54","first-page":"A1026","article-title":"A multicenter trial of anti-tumor necrosis factor (tnf) antibody (ca2) for treatment of patients with active Crohn's disease","volume":"110","author":"Targan","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.03.001_BIB55","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855304000305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855304000305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T22:52:01Z","timestamp":1586213521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855304000305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0889855304000305"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2004.03.001","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}